---
title: "UBS lowers PA GOODDOCTOR's target price to 14.5 yuan, rating \"Neutral\""
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/280577734.md"
description: "UBS released a report, lowering the target price for PA GOODDOCTOR to 14.5 yuan, with a rating of \"Neutral.\" The company's revenue last year grew by 13.7% year-on-year to 5.47 billion yuan, with a net profit of 378 million yuan, and a non-International Financial Reporting Standards net profit of 414 million yuan. The net profit margin and adjusted net profit margin increased to 6.9% and 7.6%, respectively. Revenue growth was mainly driven by an increase in the number of paying users and user spending, while the improvement in profit margins was attributed to business portfolio optimization and enhanced operational efficiency"
datetime: "2026-03-26T06:40:09.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280577734.md)
  - [en](https://longbridge.com/en/news/280577734.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280577734.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/280577734.md) | [English](https://longbridge.com/en/news/280577734.md)


# UBS lowers PA GOODDOCTOR's target price to 14.5 yuan, rating "Neutral"

UBS published a research report stating that PA GOODDOCTOR (01833.HK) had a revenue increase of 13.7% year-on-year to RMB 5.47 billion last year, with net profit and non-IFRS net profit reaching RMB 378 million and RMB 414 million respectively, indicating net profit margins and adjusted net profit margins of 6.9% and 7.6%, an increase of 5.2 and 4.3 percentage points year-on-year.

The bank indicated that the group's revenue met expectations, and net profit exceeded market expectations; revenue growth was driven by a stable increase in the number of paying users and increased user spending, while profit margin growth was driven by business portfolio optimization, improved operational efficiency, and one-time gains related to litigation, which outperformed expectations.

The bank raised its earnings per share forecast for the group for each year from this year to 2028 to RMB 0.22, RMB 0.31, and RMB 0.39, and lowered its target price from HKD 16.5 to HKD 14.5, maintaining a "Neutral" rating

### 相關股票

- [Guotai SSE STAR Brand Name Drug ETF (589720.CN)](https://longbridge.com/zh-HK/quote/589720.CN.md)
- [E Fund CSI 300 Health Care ETF (512010.CN)](https://longbridge.com/zh-HK/quote/512010.CN.md)
- [Dacheng CSI All Share Health Care Equipment and Services ETF (516610.CN)](https://longbridge.com/zh-HK/quote/516610.CN.md)
- [GF CSI HK Innovative Drugs Industry ETF(QDII) (513120.CN)](https://longbridge.com/zh-HK/quote/513120.CN.md)
- [ChinaAMC SSE Health Care ETF Initiating Fund (510660.CN)](https://longbridge.com/zh-HK/quote/510660.CN.md)
- [PA GOODDOCTOR (01833.HK)](https://longbridge.com/zh-HK/quote/01833.HK.md)
- [China Universal 800 Health Care ETF (159929.CN)](https://longbridge.com/zh-HK/quote/159929.CN.md)

## 相關資訊與研究

- [Jefferies Reaffirms Their Hold Rating on Ping An Healthcare and Technology Company (PANHF)](https://longbridge.com/zh-HK/news/280867231.md)
- [Xinhua Pharma Becomes Marketing Authorization Holder of Dental Drug After Regulatory Nod](https://longbridge.com/zh-HK/news/281343251.md)
- [XD Inc. Profit Nearly Doubles in 2025 Despite User Declines in Gaming](https://longbridge.com/zh-HK/news/280725920.md)
- [Seres Group Refines AGM Agenda With Detailed Share Buyback Resolutions](https://longbridge.com/zh-HK/news/281431575.md)
- [Biocytogen and Sihuan partner to advance new therapeutics for weight loss](https://longbridge.com/zh-HK/news/281501537.md)